BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 11385497)

  • 1. A dominant-negative therapy for anthrax.
    Leppla SH
    Nat Med; 2001 Jun; 7(6):659-60. PubMed ID: 11385497
    [No Abstract]   [Full Text] [Related]  

  • 2. Dominant-negative mutants of a toxin subunit: an approach to therapy of anthrax.
    Sellman BR; Mourez M; Collier RJ
    Science; 2001 Apr; 292(5517):695-7. PubMed ID: 11326092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioterrorism. Researchers question obsession with Cipro.
    Enserink M
    Science; 2001 Oct; 294(5543):759-61. PubMed ID: 11679638
    [No Abstract]   [Full Text] [Related]  

  • 4. Editorial.
    Mock M; Montecucco C
    Mol Aspects Med; 2009 Dec; 30(6):345-6. PubMed ID: 19733583
    [No Abstract]   [Full Text] [Related]  

  • 5. Microbiology. Fighting anthrax with a mutant toxin.
    Olsnes S; Wesche J
    Science; 2001 Apr; 292(5517):647-8. PubMed ID: 11330322
    [No Abstract]   [Full Text] [Related]  

  • 6. Inhibition of the proteolytic activity of anthrax lethal factor by aminoglycosides.
    Lee LV; Bower KE; Liang FS; Shi J; Wu D; Sucheck SJ; Vogt PK; Wong CH
    J Am Chem Soc; 2004 Apr; 126(15):4774-5. PubMed ID: 15080670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioterrorism. This time it was real: knowledge of anthrax put to the test.
    Enserink M
    Science; 2001 Oct; 294(5542):490-1. PubMed ID: 11641469
    [No Abstract]   [Full Text] [Related]  

  • 8. Plasmid-based vaccination with candidate anthrax vaccine antigens induces durable type 1 and type 2 T-helper immune responses.
    Zhang Y; Qiu J; Zhou Y; Farhangfar F; Hester J; Lin AY; Decker WK
    Vaccine; 2008 Jan; 26(5):614-22. PubMed ID: 18166249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anthrax: a molecular full nelson.
    Liddington RC
    Nature; 2002 Jan; 415(6870):373-4. PubMed ID: 11807530
    [No Abstract]   [Full Text] [Related]  

  • 10. Anthrax, toxins and vaccines: a 125-year journey targeting Bacillus anthracis.
    Tournier JN; Ulrich RG; Quesnel-Hellmann A; Mohamadzadeh M; Stiles BG
    Expert Rev Anti Infect Ther; 2009 Mar; 7(2):219-36. PubMed ID: 19254170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New developments in vaccines, inhibitors of anthrax toxins, and antibiotic therapeutics for Bacillus anthracis.
    Beierlein JM; Anderson AC
    Curr Med Chem; 2011; 18(33):5083-94. PubMed ID: 22050756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combating the threat of anthrax: a quantitative structure-activity relationship approach.
    Verma RP; Hansch C
    Mol Pharm; 2008; 5(5):745-59. PubMed ID: 18611038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening inhibitors of anthrax lethal factor.
    Tonello F; Seveso M; Marin O; Mock M; Montecucco C
    Nature; 2002 Jul; 418(6896):386. PubMed ID: 12140548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interactions between anthrax toxin receptors and protective antigen.
    Scobie HM; Young JA
    Curr Opin Microbiol; 2005 Feb; 8(1):106-12. PubMed ID: 15694864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Learning from the 2001 anthrax attacks: immunological characteristics.
    Hadler JL
    J Infect Dis; 2007 Jan; 195(2):163-4. PubMed ID: 17191158
    [No Abstract]   [Full Text] [Related]  

  • 16. Tackling anthrax.
    Friedlander AM
    Nature; 2001 Nov; 414(6860):160-1. PubMed ID: 11700539
    [No Abstract]   [Full Text] [Related]  

  • 17. Potential biological targets of Bacillus anthracis in anti-infective approaches against the threat of bioterrorism.
    Bouzianas DG
    Expert Rev Anti Infect Ther; 2007 Aug; 5(4):665-84. PubMed ID: 17678429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bacterial protein toxins. An overview.
    Alouf JE
    Methods Mol Biol; 2000; 145():1-26. PubMed ID: 10820713
    [No Abstract]   [Full Text] [Related]  

  • 19. War against anthrax.
    Khanna H; Singh Y
    Mol Med; 2001 Dec; 7(12):795-6. PubMed ID: 11844866
    [No Abstract]   [Full Text] [Related]  

  • 20. A recombinant 63-kDa form of Bacillus anthracis protective antigen produced in the yeast Saccharomyces cerevisiae provides protection in rabbit and primate inhalational challenge models of anthrax infection.
    Hepler RW; Kelly R; McNeely TB; Fan H; Losada MC; George HA; Woods A; Cope LD; Bansal A; Cook JC; Zang G; Cohen SL; Wei X; Keller PM; Leffel E; Joyce JG; Pitt L; Schultz LD; Jansen KU; Kurtz M
    Vaccine; 2006 Mar; 24(10):1501-14. PubMed ID: 16271808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.